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Abstract 1 
 2 
Idiopathic epilepsy (IE) is one of the most common chronic neurological conditions in the dog; 3 
estimated to affect 0.6%-0.75% of dogs. Owners of dogs with IE have previously indicated that their 4 
dog’s quality of life (QoL) is of greatest importance to them above their seizure frequency; however, 5 
much of the research into canine IE to date has focussed on seizure frequency, and how to reduce it 6 
via anti-epileptic drug treatment. In humans, the impact of epilepsy upon QoL has been widely studied, 7 
exploring its impact on physical health, but also the psychological health and cognitive capabilities of 8 
affected individuals. This paper reviews the existing literature on canine IE, identifying potential 9 
threats to QoL, drawing parallels from human epilepsy research. We suggest that canine IE poses 10 
threats to both quality and quantity of life, with treatment interventions posing a fine balance of 11 
potential benefits and harms to the patient. At present, little is known about the neurobehavioural, 12 
emotional and cognitive effects of IE upon affected dogs, with further studies needed to establish the 13 
extent to which unknown QoL-inhibiting comorbidities exist in the dog, to avoid their undertreatment. 14 
More in-depth studies are required to objectively quantify the effects of IE on QoL 15 
 16 
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Epilepsy and Quality of Life 35 
 36 
Idiopathic epilepsy (IE) is defined as epilepsy of predominantly genetic or presumed genetic origin and 37 
in which there are no gross neuroanatomical or neuropathological abnormalities nor other relevant 38 
underlying diseases causing seizure activity (Shorvon 2014). IE is the most common chronic 39 
neurological condition in domestic dogs, and although the true prevalence is unknown, it has been 40 
estimated to be 0.6% – 0.75% in the general canine population (Heske and others 2014; Kearsley-Fleet 41 
and others 2013). Age of onset is most commonly between 6 months and 6 years (Armaşu and others 42 
2014) and the condition is lifelong, in some cases requiring constant medication. Owners of dogs with 43 
IE have previously indicated that their dog’s quality of life (QoL) is of greatest importance to them 44 
above their seizure frequency (Chang and others 2006a); however, much of the research into canine IE 45 
to date has focussed on seizure frequency, and how to reduce it via anti-epileptic drug (AED) treatment 46 
e.g. (Dewey and others 2009; Dowling 1994; Pearce 1990) with little consideration of QoL until recent 47 
years, which has been heavily focussed on the owner’s QoL (Chang and others 2006b; Wessmann and 48 
others 2014). In humans, the impact of epilepsy upon QoL has been widely studied, exploring the 49 
holistic impact of epilepsy on physical health, but also the psychological health and cognitive 50 
capabilities of affected individuals (Elger and others 2004). Indeed, QoL scoring systems for people 51 
with epilepsy cover a broad range of topics. For example, the Quality of Life in Epilepsy (QOLIE-89) 52 
inventory (Devinsky and others 1995), summarised in Table 1, comprises diverse topics, some of 53 
relevance to canine IE (e.g. ‘medication effects), while others are human-centric (e.g. 54 
‘work/driving/social). These impacts on QoL are not simply those that impact physical and mental 55 
directly, but also indirect effects that decrease opportunities to participate in activities that promote 56 
QoL.  57 
 58 
Previously, the impact of IE on canine welfare has been judged as mild-moderate, with a general illness 59 
severity index score of 4-10 out of 16 (Asher and others 2009; Summers and others 2010). This 60 
comprised a prognosis score of 2-3/4, treatment 2-3/4, complications 0-2 and behaviour 0-2. As that 61 
review was an overarching assessment of all disorders considered to be inherited in dogs, justification 62 
of each score was not provided. This review will consider the potential impact of IE on canine welfare, 63 
QoL, and highlight areas of epilepsy-related QoL compromise in humans that require further study in 64 
canine patients. Issues of both quality of life (threats to emotional state) and quantity of life (threats to 65 
longevity) will be considered as they are both of importance to companion animal owners. An overview 66 
of areas reviewed is depicted in Figure 1. 67 
 68 
  69 
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Are seizures per se a welfare problem? 70 
 71 
The most salient feature of IE, and target of treatment is the epileptic seizure. Human epilepsy research 72 
has the advantage that many epilepsy patients can vocally self-report their experiences, and the effect a 73 
seizure has upon them. To date, no studies have objectively measured the impact of a seizure event on 74 
the affective state of a dog (e.g. through physiological or behavioural analysis such as cognitive bias 75 
testing, which has detected negative emotional states in dogs previously (Harding and others 2004; 76 
Mendl and others 2010)). As such, estimating the mental effects at present is limited to behavioural 77 
observations (which are often anecdotal rather than systematically studied), and considering comparable 78 
effects in humans. The welfare impact of a seizure may depend on the seizure type and severity due to 79 
variability in the dog’s awareness of the event, and the capacity for physical harm. In addition, each 80 
phase of the seizure (prodrome, ictal and post-ictal phases) may have a different impact on the mental 81 
state of the dog, although all three phases do not occur in all seizures. 82 
 83 
Prodrome 84 
In some dogs, seizures are be preceded by a prodromal phase, a long-term change in disposition and 85 
indicator of forthcoming seizures, occurring over hours to days. Signs may include abnormal behaviours 86 
such as anxiety, restlessness, irritation, and attention-seeking (Skerritt 1988). Owners may be able to 87 
identify these behaviours as predictors of seizure activity. Whether dogs can learn to predict the onset 88 
of a seizure, and experience negative anticipation during this phase is not known; however, retrograde 89 
amnesia may occur after a generalised seizure due to loss of consciousness impairing normal brain 90 
processes, disrupting the encoding and storage of information (Butler and Zeman 2008). The 91 
behavioural signs of the prodromal phase are in line with this being a negative affective experience, 92 
with anxiety and mood changes also reported in people with epilepsy during this phase, including 93 
tension, uneasiness or, alternatively, sadness, apathy and indifference (Scaramelli and others 2009). 94 
 95 
Ictal phase 96 
Seizures can be generalised i.e. affecting both cerebral hemispheres or focal, where the abnormal 97 
electrical activity is limited to a specific area or areas of the brain. Focal seizures occur when abnormal 98 
electrical activity arises in a specific area of the brain, resulting in divergent clinical signs dependent on 99 
the function of the area involved. Focal seizures have been reported in dogs with IE (Berendt and others 100 
2009; Licht and others 2007; Patterson and others 2005; Patterson and others 2003), as well as 101 
symptomatic epilepsy. Focal seizures can occur with or without a reduction in consciousness. Prior to 102 
the revised classification, focal seizures were categorised in humans based on consciousness status, with 103 
consciousness maintained with simple focal seizures, and consciousness impaired in complex focal 104 
seizures (with the patient self-reporting their consciousness state post-seizure) (Berg and others 2010). 105 
In dogs, as vocal self-report is not possible, assessments of consciousness are dependent upon observers 106 
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assessments, which are often unreliable (Packer and others 2015a).  Focal motor, sensory, autonomic, 107 
or psychic behavioural signs can occur (Berendt and others 2004). Focal motor seizures often occur as 108 
localised motor phenomena, such as rhythmic twitching of an extremity and abnormal rhythmic 109 
blinking, during which the dog is often presumed to be conscious. Focal seizures with a parasympathetic 110 
component may present as vomiting, hypersalivation, or dilation of the pupils, while focal seizures with 111 
a sensory of psychic component often manifest as behavioural changes, including anxious behaviours, 112 
restlessness, pacing, and seeking out their owner (Berendt and others 2004). The latter may have been 113 
described in humans as usually dominated by unpleasant or frightening sensations, including 114 
unexplained feelings of fear and apprehension (Ali and others 2012; Lennox and Lennox 1960). It is 115 
possible that in rare cases, certain types of seizure may be painful. Among human epilepsy patients with 116 
somatosensory seizures, whereby the seizure arises from sensory areas in the parietal lobe, pain was 117 
found in 23.6% of seizures (Mauguiere and Courjon 1978). In one study of 858 human epilepsy patients, 118 
2.8% (n=24) had experienced painful seizures (Young and Blume 1983), and in a further study, 1.4% 119 
(n=8) of 573 epilepsy patients (Siegel and others 1999). In these cases, involvement of the primary 120 
somatosensory cortex in the parietal lobe was again suspected rather than conscious awareness of 121 
painful involuntary motor movements during the seizure (Young and Blume 1983). Pain from 122 
headaches has also been associated with seizures as a preictal, ictal or postictal phenomenon, which is 123 
often neglected due to the dramatic neurological manifestations of the seizure (Dainese and others 2011) 124 
 125 
Focal seizures can develop into generalised seizures, by spreading through subcortical structures to 126 
involve the entire brain, termed ‘focal seizure with secondary generalisation’. The initial localisation of 127 
signs during the focal seizure (which may be very brief) is followed by a generalised seizure, with the 128 
focal seizure potentially missed by an observer. Generalised seizures are characterised by bilateral 129 
involvement (both sides of body) indicating that both cerebral hemispheres are involved. Generalised 130 
seizures are seen predominantly as tonic (stiffening), clonic (jerking), or tonic-clonic seizures; however, 131 
myoclonic seizures can occur (with sporadic jerks affecting both sides of the body) and non-convulsive 132 
generalised seizures, termed atonic seizures, or ‘drop attacks’(where a sudden loss of muscle tone 133 
causes collapse). During generalised seizures, it is widely accepted that total amnesia and loss of 134 
consciousness occur in humans (Goldensohn and others 1984). Although we cannot truly know the 135 
experience of a dog during a seizure, dogs are also thought to be unconscious and thus unaware of the 136 
event during a generalised seizure and thus protected from mental distress (except in myoclonic 137 
seizures). During this phase, dogs are at risk of physical injury due to uncontrolled motor movements, 138 
including uncontrolled chewing leading to tongue injuries. 139 
 140 
Status epilepticus 141 
 142 
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During the ictal phase dogs are at risk of status epilepticus (SE), a prolonged seizure classed as a 143 
neurological emergency due to high mortality rates of up to 25% (Bateman and Parent 1998), and a 144 
significantly shorter survival time than dogs with IE that have not experienced SE (Saito and others 145 
2001). A poor outcome (death or euthanasia) is significantly associated with loss of seizure control after 146 
6 hours of hospitalisation (Bateman and Parent 1998). Definitions of SE vary, and include (i) a 147 
continuous epileptic seizure lasting longer than (i) five or (ii) ten minutes, (iii) up to 30 minutes or 148 
longer, or (iv) two seizures with incomplete recovery of consciousness interictally, with (i) and (iv) 149 
used most commonly in veterinary medicine (Bateman and Parent 1998; Patterson 2014; Saito and 150 
others 2001; Zimmermann and others 2009). In a hospital population of dogs with SE, over one third 151 
of dogs with SE (37.5%) had IE (Zimmermann and others 2009). SE occurs in two stage, the first 152 
characterised by generalised tonic-clonic seizures and an increase in autonomic activity, followed after 153 
approximately thirty minutes by hypotension, hypoglycaemia, hyperthermia, hypoxia, decreased 154 
cerebral blood flow, cerebral oedema and increased intracranial pressure. The sustained muscle 155 
contractions during SE, along with impaired ventilation can cause lactic acidosis, hyperkalaemia, 156 
hypercarbia and severe myoglobinuria, which may result in impaired renal function (Platt and 157 
McDonnell 2000). SE requires prompt treatment to control the seizure, with prolonged seizure activity 158 
leading to the development of circuits in the brain allowing the seizure to become self-sustaining 159 
(Manno 2003). In humans, SE has consistently been associated with long-term cognitive problems, and 160 
widespread neuronal cell loss in the brain (Wasterlain and others 1993). In rat models of epilepsy, SE 161 
in adult rats results in long-term disturbances in learning and memory, and increases susceptibility to 162 
further seizures (Cilio and others 2003).  Longitudinal follow-up of canine SE cases are needed to 163 
provide insights into the physical and mental effects of SE in dogs, and whether they are physically 164 
and/or mentally compromised after these events. 165 
 166 
Seizure severity 167 
 168 
Seizures between and within dogs may vary greatly in severity, including duration and intensity of ictal 169 
signs. Associations have been found between seizure severity and QoL in human patients, with 170 
correlations between QoL and cognitive function, social functioning and the degree the patient worries 171 
about seizures (Harden and others 2007). Further human studies have found that seizure severity is 172 
negatively associated with QoL score (Gromov and others 2005), and that this effect is independent of 173 
seizure frequency (which may otherwise confound this result) (Bautista and Tannahill Glen 2009). 174 
Objective measures of seizure severity have not yet been devised in canine IE patients, or the effect of 175 
severity on QoL studied. 176 
 177 
Post ictal phase 178 
 179 
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During the postictal phase, the brain regains normal function, with this phase lasting from minutes to 180 
hours.  The dog may appear tired, ataxic and disorientated. In humans, muscles may be sore after a 181 
generalised seizure due to the accumulation of lactic acid during the seizure (Orringer and others 1977). 182 
Dogs may also be thirsty and hungry in this period, and show behavioural signs such as aggression, 183 
hyperexcitability and fearful behaviours such as hiding, and seeking their owner’s attention, which may 184 
indicate a state of distress. As in humans (Sadeh and others 1983), some dogs appear to be blind during 185 
this phase, which although transient has the potential to cause confusion and distress. 186 
 187 
Cluster seizures 188 
 189 
Time between seizures often varies markedly both within and between dogs. Some dogs with IE 190 
experience cluster seizures (CS), defined as two or more seizures within a 24-hour period in which the 191 
patient regains consciousness between seizures (Patterson 2014; Thomas 2010), with reports of 38% 192 
(Short and others 2011) to 77% of dogs with epilepsy experiencing CS depending on the population 193 
investigated (Fredso and others 2014; Monteiro and others 2012). CS likely reduces quality and quantity 194 
of life, as dogs with a history of CS are less likely to achieve seizure-freedom following treatment 195 
(Packer and others 2014), experience a decreased survival time (Arrol and others 2012; Berendt and 196 
others 2007; Monteiro and others 2012; Saito and others 2001) and an increased likelihood of euthanasia 197 
(Fredso and others 2014) compared to dogs with single seizure episodes. Dogs may not fully recover 198 
from a preceding ictal period before another begins; however, further research is needed to determine 199 
the effect of temporally dense seizures compared to single seizures on canine welfare. 200 
 201 
Inter-ictal phase 202 
 203 
In veterinary medicine, much of the focus on the diagnosis and treatment of canine IE has focused on 204 
the seizures themselves, with research into the inter-ictal period relatively neglected. In contrast, in 205 
human epilepsy, much attention is upon the detection and treatment of inter-ictal changes and 206 
comorbidities. Although dogs with IE appear ‘neurologically normal’ between seizures (i.e. they have 207 
an unremarkable neurological examination) (Skerritt 1988), a recent study indicates that similarly to 208 
people with epilepsy, behavioural changes may be present in these dogs (Shihab and others 2011). Inter-209 
ictal changes in behaviour, emotion and cognition that may affect QoL will now be considered in people 210 
with epilepsy, with evidence from canine IE described where available. 211 
 212 
Neurobehavioural impact of epilepsy 213 
 214 
The prevalence of psychiatric disorders in people with epilepsy is higher than in either the general 215 
population or patients with other chronic medical diseases (Boro and Haut 2003; Gaitatzis and others 216 
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2004; Kobau and others 2006), with the most common disorders being depression and anxiety disorders, 217 
followed by psychoses and attention-deficit disorders (Boro and Haut 2003; Dunn and Austin 1999; 218 
LaFrance Jr. and others 2008; Prueter and Norra 2005; Seminario and others 2009). A bidirectional 219 
relationship between epilepsy and psychiatric disorders such as depression has been considered, with 220 
potentially common operant pathogenic mechanisms in the disorders that facilitate the occurrence of 221 
one in the presence of the other (Kanner 2003). This is supported by people with epilepsy being at 222 
greater risk of developing depressive disorders, but patients with depressive disorders also being at 223 
higher risk of epilepsy (Forsgren and Nystrom 1999). As such, epilepsy can be considered a more 224 
general brain disorder, which is not limited to seizure activity.  225 
 226 
Anxiety and depression 227 
 228 
In a study of health-related QoL (HRQoL) in people with epilepsy, inter-ictal anxiety and depression 229 
were found to have adverse effects on HRQoL, with their effects greater than those of seizure frequency, 230 
severity and chronicity (Johnson and others 2004). In addition, although co-morbidity was observed 231 
between anxiety and depression, their negative effects on HRQoL were found to be independent of one 232 
another (Johnson and others 2004). Despite the high prevalence of depression and anxiety in people 233 
with epilepsy, these and other psychiatric disorders are thought to be underrecognised and undertreated 234 
in both children and adults with epilepsy (Ettinger and others 1998; Gilliam and Kanner 2002; Kanner 235 
and Palec 2000; O'Donoghue and others 1999; Wiegartz and others 1999).  236 
 237 
To date, few studies have considered the possibility of psychiatric co-morbidities in dogs with IE. In 238 
one study, at least one behaviour had changed since the onset of IE in 71% of all dogs studied (Shihab 239 
and others 2011). Dogs with IE showed behavioural changes including excessive fear/anxiety, abnormal 240 
perception (e.g. barking without apparent cause), abnormal reactivity, attachment disorder, demented 241 
behaviour, apathetic behaviour and aggression (Shihab and others 2011). Some of these changes were 242 
present in dogs who were not receiving AEDs, demonstrating they are not merely a treatment side effect. 243 
The authors considered the increases in anxiety and defensive aggression comparable to anxiety 244 
disorders seen in people with epilepsy  (LaFrance Jr. and others 2008). After the onset of IE, dogs in 245 
this population began to act more anxiously or fearfully when approached by unfamiliar dogs or people, 246 
when in unfamiliar surroundings, or when faced with sudden or unpredicted movements. They acted 247 
more aggressively when being handled, when approached by other dogs or unfamiliar people, or when 248 
strangers passed by the house. These effects have the potential to adversely affect QoL due to the 249 
induction of chronic negative emotional states, and impairment of social interactions with conspecifics 250 
and/or humans.  251 
 252 
Psychoses 253 
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Psychoses are the third most common psychiatric comorbidity in people with epilepsy, and can be 254 
accompanied by hallucinations, delusions, reduced connection to reality, and impaired thought [36]. 255 
Although lack of self-report in dogs impairs our ability to detect psychosis, behaviours that may indicate 256 
these signs can be observed. A hallucination is defined as sensory perception in the absence of external 257 
stimuli, and in dogs this may manifest as barking without apparent cause, chasing shadows or light 258 
spots, aimless pacing, and staring into space. These signs of abnormal perception were detected in dogs 259 
following the onset of epilepsy (Shihab and others 2011), and if dogs are conscious during these 260 
episodes, then they could induce fear and distress, and could lead to further behavioural problems if 261 
reinforced by the owner (e.g. through increased attention or attempted punishment to stop the 262 
behaviour). Hallucinations may be challenging to differentiate from sensory focal seizures, and whether 263 
they occur in dogs requires further study. 264 
 265 
Attention-deficit/hyperactivity disorder 266 
Finally, attention-deficit/hyperactivity disorder (ADHD) is the fourth most common psychiatric co-267 
morbidity of epilepsy, with around one third of epilepsy patients diagnosed with ADHD (Thome-Souza 268 
and others 2004). In a recent large community-based survey, ADHD symptoms were self-reported in 269 
nearly one of five adults with epilepsy, which was associated with are increased psychosocial morbidity 270 
and lowered QoL (Ettinger and others 2015). Hallmarks of ADHD e.g. easy distraction and slow 271 
learning have also been demonstrated in a strain of epilepsy-model laboratory rats in various 272 
behavioural paradigms, with a disinhibited or impulsive behavioural style (Anisman and McIntyre 273 
2002). In a recent single breed study of  Lagotto Romagnolo dogs with a history of Benign Familial 274 
Juvenile Epilepsy (BFJE), an epilepsy syndrome in which dogs often experience spontaneous seizure 275 
remission before 13 weeks of age, dogs with BFJE (n=25) showed significantly higher scores on the 276 
behavioural factors ‘Inattention’ and ‘Excitability/Impulsivity’ than did the control group of Lagotto 277 
Romagnolo dogs without BFJE (Jokinen and others 2015). Recent data indicates that the three most 278 
prominent behavioural domains of dogs with IE were excitability, chasability and attachment/attention 279 
seeking, mirroring behavioural traits of humans with epilepsy and ADHD in a variety of breeds (Packer 280 
and others, Submitted). In contrast, the ‘trainability’ behavioural domain was relatively low, with two 281 
thirds of owners reporting that their dog is ‘always’ easily distracted by interesting sights, sounds and 282 
smells. These signs may lead to punishment from owners to stop these undesirable behaviours, and have 283 
an impact on their cognitive abilities due to poor attention skills. 284 
 285 
Cognitive impact of epilepsy 286 
 287 
Cognition is broadly defined as the ways in which an individual takes in information about the world 288 
through the senses, processes, retains and decides to act on it, which includes perception, learning, 289 
memory and decision making (Shettleworth 2001).  There is a predisposition to cognitive deficits in 290 
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people with epilepsy; however, to the authors’ knowledge, this has not yet been studied in dogs with 291 
epilepsy. Epilepsy per se has been found to induce or exacerbate underlying cognitive impairments, 292 
with a variety of factors contributing to these deficits, including the seizure type and age of onset 293 
(Motamedi and Meador 2003). The degree of compromise is diverse, with IEs having a milder 294 
deterioration than symptomatic epilepsy (Elger and others 2004). Intellectual abilities of people with IE 295 
are usually in the normal range, but lower than the general population (Mirsky and others 2001). 296 
Compared to healthy siblings, children with IE have a reduced memory performance and psychomotor 297 
speed despite normal intelligence (Bailet and Turk 2000). The main area of compromise for people with 298 
IE is thought to be attention-related, with patients impaired in visual and auditory sustained attention 299 
(Mirsky and others 2001), and have been reported across all seizure types in children with IE (Bhise 300 
and others 2010). These problems with attention are frequently observed in IE, irrespective of the 301 
intellectual level of the patient (Williams 2003). If present in dogs, impaired attention may result in 302 
reduced ‘trainability’ i.e. the ability to learn new commands from their owner. Although this may not 303 
have a direct impact on QoL, the consequences of this inability to sustain attention may result in the 304 
perpetuation of undesirable behaviours and inappropriate punishment from owners. 305 
 306 
The presence of neurobehavioural abnormalities in dogs with IE is poorly studied at present, and thus 307 
strategies to avoid their development, or ameliorate their effect if present is unknown. Identifying dogs 308 
at risk of these changes is a priority, and may be linked with drug response, with drug-resistant rats 309 
having greater behaviour changes than drug-responsive rats  (Gastens and others 2008). Further study 310 
into the causal mechanisms underlying the association between epilepsy and neurobehavioural changes 311 
is needed, as common mechanistic pathways may underlie these problems, and offer a common 312 
therapeutic pathway. 313 
 314 
Treatment 315 
 316 
Due to the threat of seizure activity to both quality and quantity of life, canine IE therapy is aimed at 317 
reducing seizure frequency. In veterinary medicine, a positive response to therapy is defined as a ≥ 50% 318 
reduction in seizure frequency (Muñana 2013). This is the definition of AED efficacy in the majority 319 
of canine epilepsy studies (Dewey and others 2009; Dewey and others 2004; Muñana and others 2012a; 320 
Muñana and others 2012b; Platt and others 2006; Volk and others 2008; von Klopmann and others 321 
2007). This may be a problematic outcome measure as a ≥50% reduction in an initially high seizure 322 
frequency may still result in an unacceptably high seizure frequency outcome. This may not be a 323 
satisfactory outcome for the carers (the owners), with nearly one third considering only complete seizure 324 
freedom as an acceptable outcome (Wessmann and others 2012). 325 
 326 
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QoL is decreased in people with epilepsy by poor seizure control and increased seizure severity 327 
(Johnson and others 2004), and as such, in human medicine the best improvements in QoL for epilepsy 328 
patients are achieved when treatment leads to remission (seizure freedom) (Birbeck and others 2002; 329 
Kwan and others 2010; Poochikian-Sarkissian and others 2008). Indeed, in one study no significant 330 
change in QoL was found after treatment for subjects that did not achieve seizure freedom (Birbeck and 331 
others 2002). Unfortunately, in veterinary medicine more than two thirds of dogs with epilepsy will 332 
continue to have seizures long-term (Arrol and others 2012; Berendt and others 2007; Berendt and 333 
others 2002; Heynold and others 1997; Packer and others 2015b) and around 20-30% will remain poorly 334 
controlled (<50% reduction of seizure frequency) despite adequate treatment with phenobarbitone (PB) 335 
and/or potassium bromide (KBr) (Podell and Fenner 1993; Schwartz-Porsche and others 1985; 336 
Trepanier and others 1998). Remission with or without medication has been observed in canine epilepsy 337 
cases, demonstrating that epilepsy in dogs is not necessarily a lifelong condition. Remission rates vary 338 
between studies and population studied, from as low as 14-15% (Berendt and others 2007; Packer and 339 
others 2014) to as high as 85% (Boothe and others 2012). As complete control of seizures is rare in 340 
dogs with IE, clinicians and owners goals for therapy are often based on minimising seizure frequency 341 
and severity (by titrating animals to the maximum tolerated dose), whilst minimising side effects of 342 
AEDs.  343 
 344 
Effects of anti-epileptic drugs 345 
 346 
Known effects 347 
Side effects of AEDs have a high potential for reducing QoL of the patients they are administered to, 348 
as they must be taken continuously (on a daily basis) to be effective, and thus effects may be chronic. 349 
In people with epilepsy, increases in AED side effects are significantly negatively associated with self-350 
reported QoL, more so than seizure frequency (Gilliam 2002). Although the range of AEDs used to 351 
treat IE in dogs differs from those used in humans, a variety of side effects have been reported that are 352 
considered to have a major contribution to the QoL of dogs with IE, including polyphagia, polydipsia, 353 
weight gain, polyuria, increased sleeping, ataxia, restlessness, pruritus, vomiting and diarrhoea 354 
(Wessmann and others 2014). The side effects of AEDs can predispose affected dogs to obesity, due to 355 
the combined effects of enhanced appetite (polyphagia) and reduced activity (sedation). Obesity may 356 
impede a dog’s ability to behave normally and predispose them to obesity-related diseases (German 357 
2006). Obesity has also been found to have a significant negative impact upon QoL of dogs with other 358 
neurological disorders (Rutherford and others 2012)/ Behavioural side effects of AEDs may also occur, 359 
with increases in abnormal reactivity (anxiety with unpredicted movements or with sudden or loud 360 
noises), attachment disorder (signs of separation anxiety), demented behaviour (reduced ability to 361 
recognize family members or familiar people, aimless pacing or wandering), and apathetic behaviour 362 
(reduced interest in activities, agitation if not allowed to sleep) observed in dogs with IE receiving 363 
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AEDs, but not drug-naïve dogs (Shihab and others 2011). Future studies of AED efficacy should ensure 364 
behavioural side effects are adequately reported alongside physical side effects, due to their potential 365 
impact on QoL. 366 
 367 
In many cases, side effects are present at their greatest intensity in the first 2-4 weeks of treatment, and 368 
subside after this period once serum levels reach a steady state (Boothe and others 2012; Podell 1998; 369 
Schwartz-Porsche and others 1985). In some dogs, side effects are permanent (Dewey 2006), with 370 
chronic effects observed particularly in dogs receiving polytherapy (more than one AED) rather than 371 
monotherapy. Dogs receiving three AEDs have been found to have a lower QoL than those on less than 372 
3 AEDs (Wessmann and others Submitted). Accordingly, for dogs with a low seizure frequency, the 373 
impact of AED side effects on QoL may be greater than the seizures themselves, and thus careful 374 
consideration must be given over the necessity of medication.  375 
 376 
Complications 377 
In addition to these known effects that can be explained by the known pharmacological properties of 378 
the drug (Zaccara and others 2007), reactions that are not dose related, are independent of the known 379 
mechanism of action of the drug can occur which may pose a threat to life, and require discontinuation 380 
of treatment (Zaccara and others 2007). Phenobarbital (PB) also has been associated with idiosyncratic 381 
adverse drug reactions, including haematological abnormalities (PBIHA, ‘phenobarbital induced 382 
haematological abnormalities’) such as neutropenia, anaemia and thrombocytopenia (Behne and 383 
Engelhardt 2010; Jacobs and others 1998; Khoutorsky and Bruchim 2008; Thrift and others 2010; 384 
Vargo and others 2007; Von Klopmann and others 2006; Weiss 2005; Weiss and Smith 2002). The 385 
prevalence of these abnormalities is variable, with estimates of 4.2%-22% (Bersan and others 2014; 386 
Haböck and Pakozdy 2012). Although up to a fifth of dogs may be affected, the effects of PBIHA on 387 
the animal may be minimal; for example, in a case series of 37 PB treated dogs, 8 dogs showed PBIHA 388 
(22%), but only 2 of these (5%) were clinically significant (Haböck and Pakozdy 2012). As such, 389 
PBIHA may only be welfare relevant in the most severely affected cases, where PB should be 390 
discontinued and another AED added (Bersan and others 2014). 391 
Long-term PB treatment has also been associated with hepatotoxicity in several studies which appear 392 
to be dose dependent (Bunch and others 1982; Dayrell-Hart and others 1991; Gaskill and others 2005; 393 
Muller and others 2000). Dogs with PB-induced hepatoxicity may exhibit a poor body condition, 394 
ascites, low serum albumin and blood urea nitrogen concentrations, moderately increases serum 395 
bilirubin concentrations, and abnormally high fasting and post-prandial bile acid concentrations (March 396 
and others 2004). As such bile acids should be monitored periodically, and PB should be avoided in 397 
patients with hepatic dysfunction. Superficial necrolytic dermatitis has been reported in dogs treated 398 
with PB chronically (March and others 2004). This condition commonly causes painful footpad lesions 399 
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resulting in lethargy, inactivity and reluctance to walk, and carries a poor prognosis, with dogs 400 
euthanased on average 12 weeks after diagnosis (March and others 2004). The prevalence of this 401 
disorder in PB-treated dogs is not known. Finally, dogs with epilepsy have been demonstrated to be at 402 
risk of acute pancreatitis (Hess and others 1999) which can cause vomiting, diarrhoea, anorexia, 403 
abdominal pain and death. This association has since been attributed to long-term treatment with PB 404 
and potassium bromide (KBr) (Gaskill and Cribb 2000), where the prevalence of suspected pancreatitis 405 
associated with KBr/phenobarbital combination therapy was at least 10%, compared with 0.3% with 406 
PB monotherapy. 407 
 408 
Ethical considerations 409 
 410 
The ethics of epilepsy treatment is complex, with a fine balance of the potential benefits of AEDs versus 411 
potential harms. This balance varies between dogs, and over an individual’s disease course. Factors that 412 
may influence this balance may include the initial seizure frequency, response to AEDs, and the number 413 
of AEDs required to provide adequate seizure control. In addition to the side effects described above, 414 
there may be iatrogenic consequences of treating epilepsy, that is, unintentional adverse effects that 415 
may occur as a by-product of diagnosis and treatment, even when used appropriately (Yeates 2012). As 416 
IE is a diagnosis of exclusion, a variety of diagnostic tests may be carried out including blood tests 417 
requiring venipuncture that may be uncomfortable and distressing to the individual, as well as invasive 418 
diagnostics requiring general anaesthesia (cerebrospinal fluid analysis and MRI of the brain) that carry 419 
a small risk of death (Brodbelt 2009). Hospitalisation to carry out these tests may be aversive to the 420 
dog, and has been associated with an increase heart rate (Väisänen and others 2005) and cortisol levels 421 
(Van Vonderen and others 1998). As dogs with epilepsy may show increases in fear/anxiety, 422 
hospitalisation may be particularly stressful, and restraint and punishment of these dogs should be 423 
avoided as they may increase fear-related behaviours (Herron and others 2009; Rosado and others 424 
2009). Once AED treatment has been initiated, regular monitoring of serum drug concentrations (PB 425 
and KBr), and blood tests (haematology/serum biochemistry) are required, with periodic checks every 426 
3-6 months, dependent upon AED and the dog’s response to it. These visits may be aversive to the dog, 427 
with veterinary practice visits increasing heart rate and blood pressure (Kallet and others 1997), cortisol 428 
(Van Vonderen and others 1998), and fear-related behaviours (Döring and others 2009). As epilepsy is 429 
a chronic condition, efforts should be made to ensure these visits are positive, as dogs with only positive 430 
previous experiences in veterinary surgeries were significantly less ‘fearful’ than dogs that had a 431 
previous negative experience (Döring and others 2009).  432 
 433 
Quantity of life 434 
 435 
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Canine epilepsy has the potential to substantially reduce quantity of life. The median longevity of 436 
102,609 owned dogs attending first opinion veterinary practices was 12.0 years (IQR 8.9–14.2) (O’Neill 437 
and others 2013). In contrast, the median age at death of dogs with epilepsy was 7.0 years in two separate 438 
studies (Berendt and others 2007; Proschowsky and others 2003). In single breed studies, the life 439 
expectancy for Irish Wolfhounds is shortened by almost 2 years in epileptic dogs compared with 440 
seizure-free relatives (Casal and others 2006); however, the lifespan of Belgian Shepherds with epilepsy 441 
was not significantly shortened, despite being the predominant cause of death (Gulløv and others 2012). 442 
Within a mixed population of dogs with epilepsy, those that died or were euthanased because of epilepsy 443 
had a shorter lifespan than those euthanased due to other causes (4 years vs. 12 years) (Berendt and 444 
others 2007). After diagnosis, the median number of years that a dog lived with epilepsy was 2.3 years 445 
(Berendt and others 2007). That study was in both pure and mixed bred dogs, and in a single breed 446 
population of Border Collies, similar results were observed, with a median survival time after first 447 
seizure of 2.07 years (Hülsmeyer and others 2010).  The majority of deaths of dogs with epilepsy are 448 
epilepsy related, with more than 60% of Irish Wolfhounds (Casal and others 2006) and 70% of Belgian 449 
Shepherds with epilepsy dying of epilepsy-related reasons (Gulløv and others 2012).  450 
 451 
Few risk factors for lifespan have been identified for dogs with epilepsy; however, in one study, bitches 452 
lived longer with epilepsy compared with males (Berendt and others 2007), and in a study of Australian 453 
Shepherds, poor seizure control and a high initial seizure frequency (≥ 10 seizure days/6 months after 454 
seizure onset) were associated with reduced survival time (Weissl and others 2012). Intact Belgian 455 
Shepherd dogs with IE have also been found to have an increased risk of being euthanased because of 456 
IE compared to neutered dogs with IE (Berendt and others 2008), which the authors attributed to a 457 
reduced seizure frequency in neutered dogs. 458 
 459 
SUDEP (sudden unexpected death in epilepsy) is defined as “sudden, unexpected, witnessed or 460 
unwitnessed, non-traumatic and non-drowning death in epilepsy, with or without evidence of a seizure 461 
and excluding documented status epilepticus” (Annegers 1997) and is a well-known risk to life 462 
(Lindsten and others 2000). Incidence rates vary between populations, but reach 10 in 1000 human 463 
patients (Téllez-Zenteno and others 2005), with risk factors including poor seizure control, nocturnal 464 
seizures, young age and being male (Opeskin and Berkovic 2003). Cases of presumed SUDEP have 465 
been reported in dogs (Berendt and others 2007; Gulløv and others 2012); however, further 466 
investigation of risk factors and its prevalence are needed. 467 
 468 
Conclusions 469 
In conclusion, IE is a prevalent disorder in the canine population, with the potential to have a chronic 470 
negative effect on affected dog’s QoL, as well as significantly reducing quantity of life. As Summarised 471 
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in Table 2, all of the Five Freedoms have the potential to be comprised by epilepsy and its treatment 472 
(Farm Animal Welfare Council 1992). Although seizures may be the most salient feature of canine 473 
epilepsy, inspiration should be sought from the field of human epilepsy, where the epilepsy patient’s 474 
QoL is viewed more holistically, considering all impacts on both their physical and mental health 475 
beyond simply seizure frequency. It is clear that further research is required to gain a fuller 476 
understanding of the extent to which dogs are affected by co-morbidities of epilepsy e.g. psychiatric 477 
disorders, which should be a focus of future study to ensure that they are not under-treated. Although 478 
seizure freedom may be the holy grail of both canine and human epilepsy treatment, clinicians and 479 
owners should not lose sight of the potential harms of treatment, and always keep this fine balance in 480 
favour of the dog’s quality of life. 481 
  482 
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Figure 1 Threats to Quality of Life in dogs with idiopathic epilepsy 
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Table 1. Scales and items that compromise the Quality of Life in Epilepsy (QOLIE-89) inventory, an instrument to measure health-related quality of life 
(HRQOL) in people with epilepsy 
 
 
 
  
Scale Item General description 
Epilepsy-
targeted 
Seizure worry Fear and worry about having a seizure 
Medication effects Physical and mental effects of AEDs 
Health discouragement Feelings of discouragement regarding epilepsy 
Work/driving/social Degree of which epilepsy impedes ‘normal’ life 
Cognitive 
Language Effect of epilepsy on ability to communicate with others 
Attention/concentration Ability to concentrate and organise complicated activities 
Memory Effect of epilepsy on memory function  
Mental health 
Emotional wellbeing Frequency of experiencing positive and negative emotions 
Role limitation: emotional Extent that emotional problems e.g. anxiety limit daily life 
Social isolation Frequency of feelings of isolation and being ‘left out’ 
Social support Quality of supportive interactions with family and/or friends 
Energy/fatigue Frequency of feeling low on energy or tired 
Physical health 
Health perceptions Perception of current and future health, and health risks 
Physical function Frequency of epilepsy preventing physical activities 
Role limitations: physical Extent that physical problems limit daily life 
Pain Severity of bodily pain and degree it interferes with daily life 
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Table 2 Potential impact of epilepsy and anti-epileptic drug treatment upon the Five Freedoms (Farm Animal Welfare Council, 1992) 
 
Five Freedoms 
Framework 
Potential impact of epilepsy upon freedom Potential impact of anti-epileptic drugs upon freedom 
Freedom from 
hunger and thirst 
Postictal hunger 
Polyphagia, polydipsia due to antiepileptic drug treatment such as 
phenobarbital and/or potassium bromide treatment 
Freedom from 
discomfort 
Venipuncture for blood tests required for diagnosis of IE  Venipuncture for blood serum monitoring 
Freedom from pain, 
injury and disease 
Injury sustained during uncontrolled motor movements of 
generalised seizure activity; Brain damage from prolonged seizure 
activity (status epilepticus); Pain of seizures in somatosensory 
cortex 
Physical side effects including polyuria (which may lead to 
incontinence), ataxia, pruritus, vomiting, diarrhoea;  
Increased risk of obesity resulting from polyphagia and lethargy;  
Increased risk of hepatotoxicity, pancreatitis, superficial necrolytic 
dermatitis and haematological abnormalities 
Freedom to behave 
normally 
Increased fear/anxiety, defensive aggression and abnormal 
perception; potential impact of behavioural abnormalities upon 
ability to interact normally with conspecifics and/or humans 
Increased fear/anxiety, abnormal perception, abnormal reactivity 
attachment disorder, demented behaviour and apathetic behaviour; 
potential impact of behavioural abnormalities upon ability to interact 
normally with conspecifics and/or humans 
Side effects of lethargy and restlessness 
Freedom from fear 
and distress 
Increased fear/anxiety; Focal seizures with a psychic behavioural 
component in which consciousness is maintained; Anxiety during 
the prodromal and/or  postictal phase; Repeated veterinary visits 
and hospitalisation including venepuncture and separation from 
owner 
Increased fear/anxiety; Repeated veterinary visits including 
venepuncture for drug serum monitoring 
 
